Although crizotinib shows moderate activity against brain metastases in TKI‐naïve ALK‐fusion‐positive lung cancers, a recurrence in CNS lesions is frequently observed at the acquisition of resistance 42, indicating the lower efficacy of crizotinib against brain metastases, compared to its efficacy against extracranial tumor lesions. This evidence concerns the gene ALK and neoplasm.